TACR1 and Alzheimer disease: Therefore, our current research work emphasizes the role of N Acetyl l Tryptophan (l-NAT) along with FDA-approved ligands as NK1R antagonists that may prove an essential candidate in curbing neuroinflammation that could aid in AD therapeutics via the NK1R system.